

Docket No. 13760-7030

3. (Amended) The method of claim 1 wherein the polypeptide is administered orally, transdermally, intravenously, intrasynovially, intramuscularly, intraocularly, intranasally, intrathecally, or topically.

A1
4. (Amended) The method of claim 1 wherein the polypeptide is administered in conjunction with another method of treating said neurological disorder.

5. The method of claim 1, wherein the neurological disorder is caused by oxidative stress response in neuronal tissue.

6. The method of claim 1, wherein the neurological disorder is caused by the activation of a neuron specific, stress-activated protein kinase.

7. The method of claim 6, wherein the protein kinase is c-Jun amino-terminal kinase 3.

A2
8. (Amended) The method of claim 1 wherein the neurological disorder is a disorder selected from dementia, dementia of the Alzheimer's type, bipolar disorders, mood disorder with depressive features, mood disorder with major depressive-like episode, mood disorder with manic features, mood disorder with mixed features, substance-induced mood disorder, mood disorder not otherwise specified (NOS), panic disorder without agoraphobia, panic disorder with agoraphobia, agoraphobia without history of panic disorder, social phobia, posttraumatic stress disorder, acute stress disorder, substance-induced anxiety disorder, anxiety disorder not otherwise specified (NOS), dyskinesias, behavioral manifestations of mental retardation, conduct disorder and autistic disorder.

9. (Amended) The method of claim 8, wherein the neurological disorder is a dementia selected from the group consisting of vascular dementia, dementia due to HIV disease, dementia due to head trauma, dementia due to Parkinson's disease, dementia due to Huntington's disease, dementia due to Pick's disease, dementia due to Creutzfeldt-Jakob disease, substance-induced persisting dementia, dementia due to multiple etiologies and dementia not otherwise specified (NOS).

Docket N . 13760-7030

10. (Amended) The method of claim 8, wherein said neurological disorder is dementia of the Alzheimer's type.

11. (Amended) The method of claim 10, wherein said dementia of the Alzheimer's type is selected from the group consisting of dementia of the Alzheimer's type with early onset uncomplicated, dementia of the Alzheimer's type with early onset with delusions, dementia of the Alzheimer's type with early onset with depressed mood, dementia of the Alzheimer's type with late onset uncomplicated, dementia of the Alzheimer's type with late onset with delusions and dementia of the Alzheimer's type with late onset with depressed mood.

A2
cancel
12. (Amended) The method of claim 1, wherein the polypeptide is administered in a targeted drug delivery system.

13. The method of claim 12, wherein the targeted drug delivery system is a liposome coated with an antibody that specifically targets neuronal tissue.

A3
17. (Amended) A method of treating a human subject for a neurological disease selected from the group consisting of Alzheimer's disease, stroke, amyotrophic lateral sclerosis, age associated memory impairment and Parkinson's disease, the method comprising administering to said human an effective amount of a polypeptide having a sequence that is substantially equivalent to SEQ ID NO: 2.

18. (Amended) The method of claim 17 wherein the polypeptide is administered in a composition further comprising a pharmaceutically acceptable carrier.

19. The method of claim 17 wherein the composition is administered orally, transdermally, intravenously, intrasynovially, intramuscularly, intraocularly, intranasally, intrathecally, or topically.

20. The method of claim 17 wherein the method is used in conjunction with another method of treating said neurological disorder.

A4
-- 21. (New) The method of claim 1, wherein the polypeptide has the sequence depicted in SEQ ID NO: 2.